21st International AIDS Conference (AIDS 2016)

July 18-22, 2016; Durban, South Africa
CCO is the official provider of online scientific analysis for the 2016 International AIDS Society meeting, through Capsule Summaries, downloadable slides, and CME-certified faculty analysis of key studies on HIV treatment and prevention.

Highlights of AIDS 2016

Capsules

Enhanced prophylaxis also associated with improvements in severe disease or death, new TB, cryptococcal or candida infection, and hospitalization in study from sub-Saharan Africa.

Released: July 24, 2016

Despite lack of impact on all-cause mortality, raltegravir-intensified ART associated with much faster reduction in HIV-1 RNA levels and greater increase in CD4+ cell counts at Week 48.

Released: July 29, 2016

Similar CD4+ cell count increases, rates of virologic failure, and safety outcomes observed for each regimen.

Released: July 26, 2016

In this pilot study, 90% of patients maintained virologic suppression through Week 48; 1 patient who had baseline HIV-1 RNA > 100,000 copies/mL experienced protocol-defined virologic failure at Week 36, and 1 patient was a victim of suicide deemed unrelated to study drugs.

Released: July 25, 2016

Whereas rates of AIDS-defining events, serious outcomes, and death were low and not different for those who stopped vs continued ART, rates of WHO stage 2/3 events were cut in half for women who continued ART in the postpartum period.

Released: July 24, 2016

Study in low- and middle-income countries included > 60% women, suggests single-tablet RPV/TDF/FTC could provide viable ART alternative for virologically suppressed HIV-infected individuals.

Released: July 29, 2016

Superiority in ITT analysis driven by fewer discontinuations due to adverse events and virologic nonresponse; no treatment-emergent resistance observed in dolutegravir/abacavir/lamivudine arm

Released: July 25, 2016

In first randomized interventional evaluation of HIV PrEP in US women, no safety or tolerability differences seen between maraviroc-containing PrEP vs TDF + FTC; no new HIV infections occurred over study course.

Released: July 21, 2016

Decreased adherence to PrEP over time aligned with increasing intervals between planned clinic visits.

Released: July 22, 2016

Switch to daily DTG plus RPV associated with improved liver function tests, improved lipid profile, and stable kidney function.

Released: July 26, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Produced in collaboration with
Educational grant provided by:
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?